Physica Medica: European Journal of Medical Physics
Volume 21 , Pages 12-16 , 2006

Radiotracer breast cancer imaging: Beyond FDG and MIBI

  • David A. Mankoff

      Affiliations

    • Corresponding Author InformationAddress for correspondence: D.A. Mankoff, Division of Nuclear Medicine, Box 356113, Room NN203, UWMC 1959 NE Pacific Street, Seattle (WA, USA) 98195. Phone: 206-288-2173; Fax: 206-598-4496.

References 

  1. Taillefer R. The role of 99mTc-sestaMIBI and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 199: 29; 16–40.
  2. Albertini J, Lyman G, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–1822
  3. Eubank W, Mankoff D. Current and future uses of PET in breast cancer imaging. Semm Nucl Med. 2004;34:224–240
  4. Eubank W, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of [F-18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. AJR Am J Roentgen. 2004;183:479–486
  5. Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol. 2004;31:20–25
  6. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573–1576
  7. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71–88
  8. Gonzalez Trotter DE, Manjeshwar RM, Doss M, Shaller C, Robinson MK, Tandon R, et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med. 2004;45:1237–1244
  9. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S80–S87
  10. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–509
  11. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and non-invasive dynamic method. Cancer Research. 1992;52:1592–1597
  12. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274–280
  13. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326–336
  14. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. Micro PET and autoradiographic imaging of breast cancer alpha V-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41–49
  15. Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BF, et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methylhalo-cgs 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 2002;29:761–770
  16. Jagoda EM, Aloj L, Seidel J, Lang L, Moody TW, Green S, et al. Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol. 2002;4:369–379
  17. Berger F, Gambhir SS. Recent advances in imaging endogenous or transferred gene expression utilizing radiom clide technologies in living subjects: applications to breast cancer. Breast Cancer Res. 2001;3:28–35
  18. Slecge GJ, McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res. 1983;38:61–75
  19. Kieswetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptales in target tissue of immature rats. J Nucl Med. 1984;25:1212–1221
  20. Inoune T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1995;11:235–245
  21. Seinbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G, et al. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 132,780). Nucl Med Biol. 2004;31:691–698
  22. Brus P, Rodig H, Romer J, Kasch H, Bergmann R, Fuchiner F, et al. Distribution of 16alpha-[18F]fluoro-estradiol-3,17beta-disulfamate in rats, tumour-bearing mice and piglets. Appl Radiat Isot. 2002;57:687–695
  23. Mirtun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–48
  24. McGuire A, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C, et al. Postron tomographic assessment of 16α-[18F]fluro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–1531
  25. Manloff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679–684
  26. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766–1774
  27. Camobell FC, Elston CW, Blamey RW, Morris AH, Nicholson RI, Griffeths K, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981;1:1317–1319
  28. Mortmer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797–2803
  29. Dowvett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452–8458
  30. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol. 1998;10(Suppl 1):S15–S19
  31. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997;3:837–847
  32. Sutherland R. Tumor hypoxia and gene expression. Acta Oncologica. 1998;37:567–574
  33. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999;59:2411–2416
  34. Rasey JS, Koh W, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiation Oncol Biol Phys. 1989;17:985–992
  35. Zheng QH, Liu X, Fei X, Wang JQ, Ohannesian DW, Erickson LC, et al. Synthesis and preliminary biological evaluation of radiolabeled O6-benzylguanine derivatives, new potential PET imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in breast cancer. Nucl Med Biol. 2003;30:405–415
  36. Aboagye EO, Price PM. Use of positron emission tomography in anticancer drug development. Invest New Drugs. 2003;21:169–181
  37. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–2252
  38. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-atsm: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  39. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research. 1993;53:977–984
  40. Ciarmiello A, Vecchio SD, Silvestro P, Potenta M, Carriero M, Thomas R, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677–1683
  41. Del Vecchio S, Ciarmiello A, Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med. 1999;43:125–131
  42. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol. 2002;29:719–727
  43. 365P Muzi M, Link JM, Mankoff DA, Collier AC, Yang X, Unadkat JD. Quantitative estimation of P-glycoprotein transport using [C-11]-verapamil. J Nucl Med. 2003;44:
  44. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [18F] fluorode-oxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689–1695
  45. Smith I, Welch A, Hutcheon A, Miller I, Payne S, Chilcott F, et al. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–1688
  46. Tannock IF. Cell proliferation. In:  Tannock IF,  Hill RP editor. The Basic Science of Oncology. New York: McGraw-Hill; 1992;p. 154–177
  47. (in press) Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2004;
  48. Cleaver JE. Thymidine metabolism and cell kinetics. Frontiers Biol. 1967;6:43–100
  49. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–156
  50. Smyczek-Gargya B, Ferris N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720–724
  51. 76P Pio BS, Park CK, Satyamurthy N, Czermin J, Phelps ME, Silverman DH. PET with fluoro-L-thmyidine allows early prediction of breast cancer rresponse to chemotherapy. J Nucl Med. 2003;44:
  52. Hockenbery D. Defining apoptosis. Am J Pathol. 1995;146:16–19
  53. Blankenberg F, Ohtsuki K, Strauss HW. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med. 1999;43:170–176
  54. Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative for identification and quantification of apoptotic cells with PET. Appl Radiat Isot. 2003;58:201–207

PII: S1120-1797(06)80016-5

doi: 10.1016/S1120-1797(06)80016-5

Physica Medica: European Journal of Medical Physics
Volume 21 , Pages 12-16 , 2006

Article Tools